Xencor Q2 2025 revenue $43.6M, net loss $30.8M; Incyte milestone $25M

Xencor Inc

2025-Q2 EPS reported -$1.07 revenue$76,340,000

Revenue $43.6M (up from $23.9M Q2 2024); net loss $30.8M ($0.41/share) vs $67.3M ($1.09) prior year.
Cash and securities $663.8M (Dec 2024: $706.7M); guidance for year-end $555-585M, runway into 2028.
Earned $25M regulatory milestone from Incyte for Monjuvi FDA approval in follicular lymphoma.
Initiated Phase 2b XENITH-UC study of XmAb942 in ulcerative colitis; plans to present XmAb819 data in Q4 2025.
Appointed Raymond Deshaies, Ph.D., to board of directors; he previously led global research at Amgen.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.